JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats573
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217333
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France116
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice93
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort81
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data75
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation64
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.61
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease61
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia55
Herpes zoster and dementia : more evidences for a causal link45
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease41
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations37
Gene and genetic therapies in Alzheimer’s disease and other dementias36
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use32
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease29
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings28
Informal care for people with dementia in Europe27
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review26
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment26
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 626
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care25
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system24
0.034343957901001